ROFI, ELEONORA
 Distribuzione geografica
Continente #
NA - Nord America 2.655
AS - Asia 1.193
EU - Europa 977
SA - Sud America 163
Continente sconosciuto - Info sul continente non disponibili 134
AF - Africa 99
OC - Oceania 10
Totale 5.231
Nazione #
US - Stati Uniti d'America 2.576
SG - Singapore 441
IT - Italia 343
CN - Cina 323
HK - Hong Kong 144
SE - Svezia 142
BR - Brasile 127
VN - Vietnam 112
DE - Germania 96
GB - Regno Unito 96
BG - Bulgaria 78
FR - Francia 63
CI - Costa d'Avorio 58
CA - Canada 53
AT - Austria 33
IN - India 33
RU - Federazione Russa 30
JP - Giappone 27
TR - Turchia 27
FI - Finlandia 24
NL - Olanda 18
BD - Bangladesh 17
SN - Senegal 13
AR - Argentina 12
PL - Polonia 11
ES - Italia 10
MX - Messico 10
AU - Australia 8
EU - Europa 8
NG - Nigeria 8
BE - Belgio 7
IQ - Iraq 7
KR - Corea 7
LT - Lituania 7
VE - Venezuela 7
PK - Pakistan 6
SA - Arabia Saudita 6
MA - Marocco 5
PH - Filippine 5
ZA - Sudafrica 5
CO - Colombia 4
CZ - Repubblica Ceca 4
EC - Ecuador 4
JM - Giamaica 4
JO - Giordania 4
KE - Kenya 4
UZ - Uzbekistan 4
CR - Costa Rica 3
ID - Indonesia 3
LV - Lettonia 3
PA - Panama 3
TW - Taiwan 3
UY - Uruguay 3
AE - Emirati Arabi Uniti 2
AZ - Azerbaigian 2
CH - Svizzera 2
EG - Egitto 2
IL - Israele 2
LB - Libano 2
LK - Sri Lanka 2
MY - Malesia 2
NP - Nepal 2
NZ - Nuova Zelanda 2
PE - Perù 2
PY - Paraguay 2
QA - Qatar 2
RO - Romania 2
TN - Tunisia 2
TT - Trinidad e Tobago 2
AL - Albania 1
AM - Armenia 1
BH - Bahrain 1
BO - Bolivia 1
BW - Botswana 1
BY - Bielorussia 1
CY - Cipro 1
DO - Repubblica Dominicana 1
ET - Etiopia 1
GR - Grecia 1
GT - Guatemala 1
GY - Guiana 1
HN - Honduras 1
HR - Croazia 1
HU - Ungheria 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
NO - Norvegia 1
OM - Oman 1
PT - Portogallo 1
SV - El Salvador 1
SY - Repubblica araba siriana 1
TH - Thailandia 1
UA - Ucraina 1
Totale 5.105
Città #
Ashburn 299
Fairfield 233
Woodbridge 218
Singapore 199
Houston 163
Santa Clara 159
San Jose 157
Hong Kong 141
Chandler 139
Seattle 112
Cambridge 82
Dallas 78
Serra 78
Sofia 78
Wilmington 78
Ann Arbor 72
Shanghai 67
New York 66
Beijing 59
Abidjan 58
London 58
Pisa 56
Boardman 53
Florence 45
Los Angeles 42
Princeton 42
Frankfurt am Main 37
Lauterbourg 33
Ottawa 33
Lawrence 31
Ho Chi Minh City 30
Vienna 30
Medford 23
Istanbul 20
Tokyo 20
Nanjing 19
Dearborn 18
Munich 18
Des Moines 16
Hanoi 16
Dong Ket 15
Rome 15
Boulder 14
Buffalo 14
Dakar 13
Redondo Beach 13
Council Bluffs 12
Chiesina Uzzanese 11
Fuzhou 11
Washington 11
Helsinki 10
Phoenix 10
Turku 10
Chicago 9
Redwood City 9
San Diego 9
San Francisco 9
São Paulo 9
Warsaw 9
Hefei 8
Lagos 8
Nuremberg 8
Columbus 7
Guangzhou 7
Kunming 7
Milan 7
Toronto 7
Bremen 6
Brussels 6
Changsha 6
Iowa City 6
Orem 6
Brooklyn 5
Bến Tre 5
Düsseldorf 5
Hyderabad 5
Montreal 5
Mumbai 5
Ogden 5
Paris 5
Turin 5
Belo Horizonte 4
Brasília 4
Chengdu 4
Chennai 4
Kilburn 4
Kingston 4
Quanzhou 4
Amman 3
Baghdad 3
Cape Town 3
Caracas 3
Charleston 3
Fortaleza 3
Genoa 3
Haiphong 3
Hebei 3
Hải Dương 3
Jiaxing 3
Lahore 3
Totale 3.587
Nome #
PD-L1 mRNA expression in plasma-derived exosomes is associated with response to anti-PD-1 antibodies in melanoma and NSCLC 329
The amount of activating EGFR mutations in circulating cell-free DNA is a marker to monitor osimertinib response 204
Overexpression of TK1 and CDK9 in plasma-derived exosomes is associated with clinical resistance to CDK4/6 inhibitors in metastatic breast cancer patients 200
Early changes in plasma DNA levels of mutant KRAS as a sensitive marker of response to chemotherapy in pancreatic cancer 199
The emerging role of liquid biopsy in diagnosis, prognosis and treatment monitoring of pancreatic cancer 195
AR-V7 and AR-FL expression is associated with clinical outcome: a translational study in patients with castrate resistant prostate cancer 191
Concise Review: Chronic Myeloid Leukemia: Stem Cell Niche and Response to Pharmacologic Treatment 189
Pharmacokinetic Markers of 5-Fluorouracil Toxicity in Clinical Trials and Real World 184
Patients with NSCLC may display a low ratio of p.T790M vs. activating EGFR mutations in plasma at disease progression: implications for personalised treatment 179
Clinical pharmacology of intravitreal anti-VEGF drugs 177
The increase in activating EGFR mutation in plasma is an early biomarker to monitor response to osimertinib: a case report 174
Detection of ALK and KRAS Mutations in Circulating Tumor DNA of Patients With Advanced ALK-Positive NSCLC With Disease Progression During Crizotinib Treatment 170
Implications of KRAS mutations in acquired resistance to treatment in NSCLC 168
Pharmacogenetics and metabolism from science to implementation in clinical practice: the example of dihydropyrimidine dehydrogenase. 166
Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical Trial 165
Comprehensive pharmacogenetic analysis of DPYD, UGT, CDA, and ABCB1 polymorphisms in pancreatic cancer patients receiving mFOLFIRINOX or gemcitabine plus nab-paclitaxel 162
Gemcitabine plus nab-paclitaxel induces PD-L1 mRNA expression in plasma-derived microvesicles in pancreatic cancer 160
Pharmacogenetics of androgen signaling in prostate cancer: focus on castration resistance and predictive biomarkers of response to treatment 156
EGFR-TKIs in non-small-cell lung cancer: Focus on clinical pharmacology and mechanisms of resistance 156
From the beginning to resistance: study of plasma monitoring and resistance mechanisms in a cohort of patients treated with osimertinib for advanced T790M-positive NSCLC 155
Dabrafenib treatment in a patient with BRAF V600E ganglioglioma: circulating exosome-derived cancer RNA supports treatment choice and clinical monitoring 152
Pharmacogenetics of CYP2D6 and tamoxifen therapy: Light at the end of the tunnel? 147
Endothelial nitric oxide synthase c.-813C>T predicts for proteinuria in metastatic breast cancer patients treated with bevacizumab-based chemotherapy 146
null 142
Primary resistance to osimertinib due to SCLC transformation: Issue of T790M determination on liquid re-biopsy 139
Erratum: Clinical pharmacology of monoclonal antibodies targeting PD-1 axis in urothelial cancers 128
Reply to Ugo De Giorgi, Vincenza Conteduca, and Emanuela Scarpi's Letter to the Editor re: Marzia Del Re, Elisa Biasco, Stefania Crucitta, et al. The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Prostate Cancer Patients. Eur Urol 2017;71:680–7 126
Concise Review: Resistance to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer: The Role of Cancer Stem Cells 124
Clinical pharmacology of monoclonal antibodies targeting anti-PD-1 axis in urothelial cancers 122
Should CYP2D6 be genotyped when treating with tamoxifen? [Letter in reply] 94
Early changes in plasma levels of mutant KRAS DNA as a sensitive marker of response to chemotherapy in pancreatic cancer 94
Should CYP2D6 be genotyped when treating with tamoxifen? 78
null 60
Totale 5.231
Categoria #
all - tutte 16.905
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 16.905


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022318 3 14 7 7 64 62 16 8 20 11 16 90
2022/2023587 59 85 45 32 49 60 1 40 148 5 61 2
2023/2024370 19 21 71 19 40 78 18 12 8 14 37 33
2024/20251.058 9 38 11 70 145 119 59 55 118 136 102 196
2025/20261.199 78 120 70 135 167 75 236 55 83 118 45 17
2026/202735 35 0 0 0 0 0 0 0 0 0 0 0
Totale 5.231